Navigation Links
Hepatitis C study shows superior viral cure rate
Date:11/2/2010

NEW YORK (November 2, 2010) -- For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis Cspecific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

The lead investigator reporting the results of the ADVANCE trial is Dr. Ira M. Jacobson, chief of the Division of Gastroenterology and Hepatology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Vincent Astor Distinguished Professor of Medicine at Weill Cornell Medical College. Dr. Jacobson presented these pivotal Phase III results today at the 61st Annual Meeting of the American Association for the Study of Liver Diseases in Boston.

Dr. Jacobson noted that 75 percent of patients treated with a telaprevir-based combination regimen for 12 weeks, followed by 12 or 36 weeks of the standard therapy of pegylated-interferon alfa-2a and ribavirin alone, achieved a viral cure. This compared to 44 percent of people treated with 48 weeks of pegylated-interferon and ribavirin alone. In addition, new data from the study showed that 62 percent of African-Americans achieved a viral cure with the telaprevir-based regimen compared to 25 percent of African-Americans who were treated with pegylated-interferon and ribavirin alone. Additionally, 62 percent of patients with advanced liver fibrosis (cirrhosis or scarring of the liver) achieved a viral cure with the telaprevir regimen compared to 33 percent who were treated with pegylated-interferon and ribavirin alone.

"These groundbreaking data, showing sustained viral response in 75 percent of patients who received 12 weeks of telaprevir combination therapy, highlight telaprevir as a potential new therapy that, if approved by the FDA, could dramatically improve the future treatment of hepatitis C," says Dr. Jacobson, who is also a hepatologist and Medical Director the
'/>"/>

Contact: Linda Kamateh
lib9027@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New screening system for hepatitis C
2. Groundbreaking research to find vaccine for hepatitis C
3. 1 in 5 At-Risk U.S. Babies Doesnt Get Hepatitis B Vaccine
4. Vaccination, Prevention Is Beating Back Hepatitis
5. Bipartisan Capitol Hill Media Event: Health Experts, Lawmakers to Urge Federal Government to Fix the Funding Failure for Chronic Viral Hepatitis
6. Hepatitis C treatment less effective in urban minority patients
7. Researchers identify potential new target for treating hepatitis C
8. Donor kidneys from Hepatitis C patients needlessly denied to patients with that infection
9. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
10. New Drug Shows Promise for Curing Hepatitis C
11. Hepatitis C Tied to Higher Kidney Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass Fiber ... defines and segments the specialty synthetic fibers and ... of the volumes and values of types such ... UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile fiber, ... fiber, and liquid crystal polymer fiber and glass ...
(Date:7/11/2014)... July 11, 2014 Datalogic brings a ... improving sanitation hospital wide. With their new Gryphon ... of disease, like the devastating MRSA, which claimed 5,500 ... GD4400-HC 2D and the Gryphon GM4400-HC 2D ... and can even read barcodes off of troublesome LCD ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... Ticket Down is a reliable source ... When it comes to the summer concert schedule, it just ... native is one of the biggest names in country music and ... currently out on his “That’s My Kind of Night” tour featuring ... will be making through the rest of the summer and into ...
Breaking Medicine News(10 mins):Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3
... 31 ev3 Inc. (Nasdaq:,EVVV) today announced that Pat ... are scheduled to present at the,Canaccord Adams 28th Annual ... p.m. Eastern Time. The Canaccord Adams 28th Annual Global,Growth ... Boston,Massachusetts., To access the webcast, go to the ...
... Call Today at 5:00 p.m. Eastern Time -, ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... progress and financial results,for the second quarter ended ... are to develop picoplatin as an oncology,platform compound ...
... July 31 Mylan Inc. (NYSE: MYL ),today ... stock,issuance, the company has declared its quarterly dividend of ... 6.5% and a liquidation,preference of $1,000.00 per share) payable ... record as of August 1, 2008., Mylan Inc., ...
... PARAMUS, N.J., July 31 Smart Balance Inc.,(Nasdaq: ... marketing organization,today. Richard McWilliams has been named to ... brands, reporting to Gregory Venner, executive,vice president and ... the marketing efforts for the Company,s core brands., ...
... ARBOR, Mich. Pat Phalin learned she had hearing loss ... her local school. The pupils heard sounds she could not ... a pattern in his wife,s family history. Her mother, grandfather ... the Phalins, children had hearing problems before he reached school ...
... ST. LOUIS, July 31 Stereotaxis, Inc. (Nasdaq:,STXS) ... results for the,second quarter ended June 30, 2008, ... The Company will host a conference call and ... Eastern Time to discuss the Company,s,second quarter results ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 2Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 3Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 4Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 5Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 6Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 7Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 8Health News:Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update 9Health News:Smart Balance Announces Marketing Organization Appointment 2Health News:Inherited form of hearing loss stems from gene mutation 2Health News:Inherited form of hearing loss stems from gene mutation 3
(Date:7/10/2014)... July 10, 2014 Decision Resources Group finds ... the U.S. Food and Drug Administration,s (FDA) approval of ... Velphoro, which was approved by the FDA in November ... disease (CKD) patients on dialysis. Other key ... (US) Q2 2014 : ...
(Date:1/15/2014)... Jan. 15, 2014 Most osteoporosis patients want a ... recent online survey* sponsored by Mission Pharmacal Company. The ... Osteoporosis Foundation online support community, revealed that 74 percent ... comes in a form other than a pill or ...
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... N.J., Oct. 30 Novo Nordisk Inc. announced the ... hemophilia(TM) campaign through a rebranded Web site and ... face many daily challenges, and Novo Nordisk is committed ... a lifetime of possibilities. , These new online resources ...
... GUANGZHOU, China, Oct. 30 ... CHME) ("China Medicine" or "the Company"), a ... pharmaceuticals,traditional Chinese medicines ("TCM"), nutritional and dietary ... announced that through its,wholly-owned subsidiary in China, ...
Cached Medicine Technology:Novo Nordisk is Changing Possibilities in Hemophilia 2Novo Nordisk is Changing Possibilities in Hemophilia 3China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 2China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 3China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: